Patient-derived xenografts (PDXs) are generated by transplanting fragments of a patient’s tumor either subcutaneously or orthotopically into immunodeficient hosts. EPO serially propagates these models in vivo and this procedure ensures that they maintain close similarities to the tumor of origin in terms of tissue architecture, molecular characteristics and response to treatments. Furthermore, our PDX models are thoroughly characterized by molecular methods such as RNA sequencing and tested for their drug response to a number of clinically relevant compounds. Apart from our proprietary PDX models, we also offer a large number of human cell-line derived xenografts (CDXs) and syngeneic models for in vivo or in vitro efficacy studies.
EPO has a long standing experience with testing anti-cancer therapies in both PDX and CDX models. These therapy options include:
- Small molecules
- Cell-mediated therapies (CAR-T cells, NK cells etc.)
- Antibody based therapies (Antibody-drug conjugates; T cell engager, NK cell engager)
- Oncolytic Microorganisms (viruses and bacteria under biosafety level 2 conditions)
Patient-derived xenografts
EPO currently offers more than 600 patient-derived xenografts of a broad variety of solid tumors including:
- Breast cancer (39 models)
- Colon cancer (183 models)
- Glioma (29 models)
- Head & neck cancer (85 models)
- Lung cancer (58 models)
- Mesothelioma (11 models)
- Neuroblastoma (22 models)
- Ovarian cancer (29 models)
- Pancreatic cancer (52 models)
- Sarcoma (73 models)
Apart from these our portfolio also includes a number of hematological tumors such as:
- Acute lymphoblastic leukemia (ALL; 10 models)
- Acute myeloid leukemia (AML; 13 models)
- B- and T-cell lymphoma (25 models)
Detailed information on these models such as molecular data (sequence variations and gene expression profiling), drug response data or clinical data are available upon request. For a comprehensive overview on our PDX cohorts we will gladly send you our informative PDF portfolio. Please contact us for more information.
From all our PDX models, we have a library of snap-frozen, Formalin-Fixed Paraffin-Embedded (FFPE), and OCT embedded tumor samples available for target identification/validation studies by immunohistochemistry (IHC). For some of our models, we also offer tissue microarrays (TMAs).
Cell line-derived xenografts and syngeneic models
Our portfolio of human cell line-derived xenografts (CDXs) and syngeneic mouse models includes more than 80 models covering all major tumor types. All tumor cell lines are regularly tested for their identity and mycoplasma negativity to ensure the highest quality standards. Tumor growth curves and data on response rates towards standard-of-care compounds are available for all of our models upon request.
